? Statistically significant difference in progression-free survival continues to be seen in non-squamous patient population
? Promising overall survival data, notably in subgroups of interest for the upcoming Phase 3 trial
? Company to hold conference call today, Monday, September 29 at 1:30 PM EDT/7:30 PM CET to discuss data
Strasbourg, France, September 29, 2014 - Transgene SA (NYSE-Euronext: TNG) today announced the presentation of more mature data from the Phase 2b part of the TIME trial with TG4010 MUC1 targeted immunotherapy at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain. The data presented show promising and consistent results in progression-free survival (PFS) and overall survival (OS), particularly in the large subgroup of patients with non-squamous disease. The poster presented at ESMO can be found on the Company's website at www.transgene.fr.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.26 (c)||1.56%||34 739|